April 24th 2025
A new study shows that varenicline combined with brief remote counseling significantly improves vaping abstinence in in patients between 16 and 25 years of age.
Fast-Tracking Innovation: The Role of Regulatory Designations in DB-OTO’s Development
March 10th 2025Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate accelerated development and commercialization of DB-OTO through increased collaboration with regulators.
Ebglyss Demonstrates Sustained Efficacy in Moderate-to-Severe Atopic Dermatitis
March 7th 2025Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved complete or near complete skin clearance at three years on a single monthly maintenance dose.
Strong Safety and Tolerability in Phase I Trials for IMU-856 Supports Broad GI Applications
February 26th 2025Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.